Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13144178 | 0.97 | ALDH1A1 (0.64) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL13144177 | 0.95 | HPGD (0.62) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL18713598 | 0.86 | SIGMAR1 (0.55) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL14094387 | 0.86 | KMT2A (0.65) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL10169258 | 0.83 | ALDH1A1 (0.96) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL13050759 | 0.83 | ALDH1A1 (0.76) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL21366588 | 0.82 | HPGD (0.61) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL23278782 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL23278783 | 0.82 | L3MBTL3 (0.71) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL19513457 | 0.81 | HPGD (0.65) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | CTXT PTY. LTD (AU) | 2020-05-12 | — | — | US | disclosed |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | PRMT5, PRMT3, PRMT1 | ALDH1A1 4354/4885KMT2A 34/4885SMN1; SMN2 2617/4885 |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT3, PRMT1 | ALDH1A1 4354/4885KMT2A 34/4885SMN1; SMN2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.